Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacutamab in Relapsed/Refractory PTCL Expressing KIR3DL2
NCT05321147Phase 1Completed
- Sponsor
- Innate Pharma
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of lacutamab in peripheral T-cell lymphoma (PTCL), sponsored by Innate Pharma. Primary endpoint: Occurrence of adverse events. Started Mar 2022; status: completed.
02
Drugs
lacutamab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05321147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321147.